We look forward to continuing to build on the momentum of this milestone and have commitments for 12 additional system upgrades to Niobe ES which will be installed over the next few months
Atlanta, GA (PRWEB) January 11, 2012
MissionIR would like to highlight Stereotaxis, Inc., a publicly traded company focused on designing, manufacturing and marketing an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The core components of the Stereotaxis systems have received regulatory clearance in the U.S., Europe, Canada and elsewhere.
In the company’s news yesterday,
Stereotaxis, Inc. announced it has completed the first 50 clinical procedures using the company’s new NiobeES™ system to treat a variety of complex cardiac arrhythmias.
The majority of the first 50 cases were performed to treat atrial fibrillation (AF), the most common type of cardiac arrhythmia. The company reports that positive initial results of the Niobe ES system in Europe demonstrate that the average time for completion of mapping and ablation for the initial AF patients was 69 minutes. The data will be featured at the Boston Atrial Fibrillation Symposium 2012 to be held on Jan. 12-14, 2012.
Stereotaxis’ Epoch™ platform encompasses the Niobe ES system, and is the company’s new generation comprehensive solution for the electrophysiology (EP) laboratory. Epoch uses a remote, networked and modular robotic, magnetic system to improve efficiency and surgical precision.
“My vision was to click on the map and for the catheter to quickly and precisely move to that spot. Today with the Epoch platform, this is a reality. I believe the Epoch platform is one of the most important innovations for the EP practice to date. With the Epoch technology all physicians can successfully and consistently perform high quality AF procedures with the assurance of superior patient care,” Professor Carlo Pappone of Villa Maria Cecilia Hospital, Cotignola Italy, stated in the press release.
Based on positive response, the company anticipates releasing a dozen product upgrades within in the next few months.
“The initial feedback and interest in our new Epoch platform has been very favorable,” said Michael P. Kaminski, president and CEO of Stereotaxis. “We look forward to continuing to build on the momentum of this milestone and have commitments for 12 additional system upgrades to Niobe ES which will be installed over the next few months.”
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
To sign up for The MissionIR Report, please visit http://MissionIR.com
To connect with MissionIR via Facebook, please visit http://Facebook.com/MissionIR
To connect with MissionIR via Twitter, please visit http://Twitter.com/MissionIR
Please read FULL disclaimer on the MissionIR website: http://Disclaimer.MissionIR.com
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.